Nuvectis Pharma Q3 2026 net loss widens to USD 30.07 million

PUBT · 1d ago
Nuvectis Pharma Q3 2026 net loss widens to USD 30.07 million
  • Nuvectis Pharma’s third-quarter 2026 net loss widened to $30.07 million.
  • Research and development expenses rose to $27.37 million, primarily driven by a $20 million upfront payment for NXP100 and NXP200 licensing.
  • Cash and cash equivalents reached $140.71 million at September 30, with funding expected to support operations into the second half of 2029.
  • An FDA update on ciprocopan’s U.S. PNH pathway and U.S. IND submissions for NXP100 and NXP200 are expected by year-end.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040700PRIMZONEFULLFEED9869601) on November 04, 2026, and is solely responsible for the information contained therein.